The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes of ponatinib in treatment of advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure.
 
Michael C. Heinrich
Stock and Other Ownership Interests - MolecularMD
Honoraria - Novartis
Consulting or Advisory Role - ARIAD; Blueprint Medicines; MolecularMD; Novartis; Pfizer
Research Funding - ARIAD (Inst); Arog (Inst); Deciphera (Inst); Inhibikase (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent on treatment of GIST-licensed to Novartis (Inst)
Expert Testimony - Novartis
 
Lisa McGarry
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
David Kerstein
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Hui Huang
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD